effect of isopropanolic cimicifuga racemosa extract on uterine fibroids in comparison with tibolone among patients of a recent randomized, double blind, parallel-controlled study in chinese women with menopausal symptoms
Clicks: 179
ID: 257588
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
179 views
12 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #514 of 899 articles by views in ACS applied materials & interfaces
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 899 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Objective. Effect of isopropanolic Cimicifuga racemosa extract (iCR) on uterine fibroid size compared with tibolone. Method. The randomized, double-blind, controlled study in China enrolled 244 patients aged 40–60 years with menopausal symptoms (Kupperman Menopause Index ≥ 15). The participants were treated with either iCR of 40 mg crude drug/day (N=122) or tibolone 2.5 mg/day (N=122) orally for 3 months in 2004. Now, we investigated the subset of all women (N=62) with at least one uterine fibroid at onset of treatment for the effect of iCR (N = 34) on fibroid size compared with tibolone (N=28) by transvaginal ultrasonography. Results. The median myoma volume decreased upon iCR by as much as −30% (P=0.016) but increased upon tibolone by +4.7%. The percentage of volume change, mean diameter change and geometric mean diameter change of the iCR group compared to tibolone were statistically significant (P=0.016, 0.021, 0.016 respectively). Conclusion. Our results suggest that iCR (Remifemin) is a valid herbal medicinal product in patients with uterine myomas as it provides adequate relief from menopausal symptoms and inhibits growth of the myomas in contrast to tibolone.
| Reference Key |
xi2014evidence-basedeffect
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Sisi Xi;Eckehard Liske;Shuyu Wang;Jianli Liu;Zhonglan Zhang;Li Geng;Lina Hu;Chunfeng Jiao;Shurong Zheng;Hans-Heinrich Henneicke-von Zepelin;Wenpei Bai |
| Journal | ACS applied materials & interfaces |
| Year | 2014 |
| DOI |
10.1155/2014/717686
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.